Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Bevacizumab in Vitrectomy for Diabetic Vitreous Hemorrhage
NCT01091896Phase 2Unknown
- Sponsor
- Universidade de São Paulo
- Start
- Jan 2010
- Primary completion
- Sep 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab in Vitreous hemorrhage (VH) (3 arms), sponsored by Universidade de São Paulo. Primary endpoint: Recurrent vitreous hemorrhage incidence after vitrectomy at 3 months. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
Vitreous hemorrhage (VH)
Beyond the preview
Go deeper on NCT01091896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01091896.